A man sued pharmaceutical giant AstraZeneca for allegedly suffering from brain injury due to a “defect” in the Covid-19 vaccine, the Independent reported.
Jamie Scott’s lawyers say he got “vaccine-induced immune thrombotic thrombocytopenia” (VITT), a rare blood-clotting condition, after getting the shot in April 2021.
47-year-old UK man faces speech issues and memory reduction after Covid vaccine, seeks compensation for brain injury
According to the outlet, the 47-year-old is suffering from “very serious injuries including speech difficulties, reduced cognition, memory and processing.” According to court documents, he’s also looking for compensation for the supposed effects of the vaccine.
As outlined in the court filing detailing Scott’s case, he got his first shot on April 23, 2021, at a clinic in Warwickshire. Ten days later, he experienced a severe headache, vomiting, and difficulty speaking, leading to an ambulance trip to the hospital, as noted by Scott’s barrister, Hugh Preston KC.
In the following weeks, he underwent “acute inpatient treatment,” including brain surgery, and now needs ongoing “multi-disciplinary rehabilitation,” according to Preston.
The lawyer added, “He struggles to complete simple domestic tasks, he has symptoms on the right side and visual difficulties, he has concentration difficulties, and suffers fatigue.”
The pharmaceutical company emphasized that patient safety is their “highest priority,” mentioning that the UK’s medicines regulator gave full marketing approval to the vaccine named Vaxzevria, Independent reported.
AstraZeneca faces claims of vaccine efficacy exaggeration amid regulatory caution
AstraZeneca, reportedly defending itself in the case, is also accused of exaggerating the effectiveness of the vaccine developed in collaboration with Oxford University, claiming they “vastly overstated” its efficacy.
On April 7, 2021, the Medicines and Healthcare Products Regulatory Agency stated that there is a “possible risk of extremely rare and unlikely to occur specific types of blood clots” after the AstraZeneca vaccine shot.
The regulator informed that the benefits of vaccination “continue to outweigh any risks” but suggested, “careful consideration be given to people who are at higher risk of specific types of blood clots because of their medical condition”.
A spokesperson for AstraZeneca said: “Patient safety is our highest priority and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines.”
“Our sympathy goes out to anyone who has lost loved ones or reported health problems.”
